These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27075581)

  • 1. In Silico Approach to Finding New Active Compounds from Histone Deacetylase (HDAC) Family.
    Yanuar A; Azminah EY; Andika EY; Erlina L; Syahdi RR
    Curr Pharm Des; 2016; 22(23):3488-97. PubMed ID: 27075581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virtual screening and experimental validation of novel histone deacetylase inhibitors.
    Huang YX; Zhao J; Song QH; Zheng LH; Fan C; Liu TT; Bao YL; Sun LG; Zhang LB; Li YX
    BMC Pharmacol Toxicol; 2016 Jul; 17(1):32. PubMed ID: 27443303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of potent HDAC 2 inhibitors using E-pharmacophore modelling, structure-based virtual screening and molecular dynamic simulation.
    Pai P; Kumar A; Shetty MG; Kini SG; Krishna MB; Satyamoorthy K; Babitha KS
    J Mol Model; 2022 Apr; 28(5):119. PubMed ID: 35419753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach.
    Hsu KC; Liu CY; Lin TE; Hsieh JH; Sung TY; Tseng HJ; Yang JM; Huang WJ
    Sci Rep; 2017 Jun; 7(1):3228. PubMed ID: 28607401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of selective histone deacetylase inhibitors: rethinking classical pharmacophore.
    Melesina J; Praetorius L; Simoben CV; Robaa D; Sippl W
    Future Med Chem; 2018 Jul; 10(13):1537-1540. PubMed ID: 29966452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inside HDAC with HDAC inhibitors.
    Bertrand P
    Eur J Med Chem; 2010 Jun; 45(6):2095-116. PubMed ID: 20223566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
    Uba AI; Yelekçi K
    J Biomol Struct Dyn; 2018 Sep; 36(12):3231-3245. PubMed ID: 28938863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Silico Identification of Potential Inhibitor Against a Fungal Histone Deacetylase, RPD3 from
    Shanmugam G; Kim T; Jeon J
    Molecules; 2019 May; 24(11):. PubMed ID: 31151320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Energy based pharmacophore mapping of HDAC inhibitors against class I HDAC enzymes.
    Kalyaanamoorthy S; Chen YP
    Biochim Biophys Acta; 2013 Jan; 1834(1):317-28. PubMed ID: 23457710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors.
    Thaler F; Moretti L; Amici R; Abate A; Colombo A; Carenzi G; Fulco MC; Boggio R; Dondio G; Gagliardi S; Minucci S; Sartori L; Varasi M; Mercurio C
    Eur J Med Chem; 2016 Jan; 108():53-67. PubMed ID: 26629860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
    Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
    Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
    Yoo J; Kim SJ; Son D; Seo H; Baek SY; Maeng CY; Lee C; Kim IS; Jung YH; Lee SM; Park HJ
    Eur J Med Chem; 2016 Jun; 116():126-135. PubMed ID: 27060764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovative Strategies for Selective Inhibition of Histone Deacetylases.
    Maolanon AR; Madsen AS; Olsen CA
    Cell Chem Biol; 2016 Jul; 23(7):759-768. PubMed ID: 27447046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Energy-optimised pharmacophore approach to identify potential hotspots during inhibition of Class II HDAC isoforms.
    Ganai SA; Shanmugam K; Mahadevan V
    J Biomol Struct Dyn; 2015; 33(2):374-87. PubMed ID: 24460542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer.
    Parbin S; Shilpi A; Kar S; Pradhan N; Sengupta D; Deb M; Rath SK; Patra SK
    Mol Biosyst; 2016 Jan; 12(1):48-58. PubMed ID: 26540192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
    Noureen N; Rashid H; Kalsoom S
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inside HDACs with more selective HDAC inhibitors.
    Roche J; Bertrand P
    Eur J Med Chem; 2016 Oct; 121():451-483. PubMed ID: 27318122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
    Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
    Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
    Tashima T; Murata H; Kodama H
    Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the epigenome: Screening bioactive compounds that regulate histone deacetylase activity.
    Godoy LD; Lucas JE; Bender AJ; Romanick SS; Ferguson BS
    Mol Nutr Food Res; 2017 Apr; 61(4):. PubMed ID: 27981795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.